HUP0003250A1 - Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0003250A1
HUP0003250A1 HU0003250A HUP0003250A HUP0003250A1 HU P0003250 A1 HUP0003250 A1 HU P0003250A1 HU 0003250 A HU0003250 A HU 0003250A HU P0003250 A HUP0003250 A HU P0003250A HU P0003250 A1 HUP0003250 A1 HU P0003250A1
Authority
HU
Hungary
Prior art keywords
optionally substituted
hydrogen atom
formula
general formula
potassium channel
Prior art date
Application number
HU0003250A
Other languages
English (en)
Inventor
George Amato
Serge Beaudoin
Neil Alexander Castle
Michael Gross
Sean Patrick Hollinshead
Philip Floyd Hughes
Grant Mcnaughton-Smith
Jose Serafin Mendoza
Joseph Wendell Wilson
Original Assignee
Eli Lilly And Co.
Icagen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co., Icagen, Inc. filed Critical Eli Lilly And Co.
Publication of HUP0003250A1 publication Critical patent/HUP0003250A1/hu
Publication of HUP0003250A3 publication Critical patent/HUP0003250A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Heads (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)

Abstract

A találmány tárgyát a káliumcsatorna gátló hatású (I), (II), (III) és(IV) általános képletű vegyületek, valamint ezeket tartalmazógyógyászati készítmények képezik. A találmány szerinti vegyületekeredményesen alkalmazhatók szívaritmia, valamint a sejtburjánzássalkapcsolatos rendellenességek kezelésére. A találmány szerinti (I)általános képletű vegyületekben a szubsztituensek jelentése akövetkező: R1 jelentése hidrogénatom, alkil-, adott esetbenszubsztituált aril-, adott esetben szubsztituált heteroaril-, adottesetben szubsztituált heterociklusos vagy adott esetben szubsztituáltkarbocikloalkilcsoport; R2 jelentése alkil-, adott esetbenszubsztituált aril-, adott esetben szubsztituált heteroaril-, adottesetben szubsztituált heterociklusos vagy adott esetben szubsztituáltkarbocikloalkilcsoport; R3 jelentése hidrogénatom vagy metilcsoport;R4 jelentése hidrogénatom vagy metilcsoport; X1 jelentése C=O, C=Svagy SO2; X2 jelentése C=O vagy SO2; Y1 jelentése O, (CH2)p, CH2O,HC=CH vagy NH, ahol a képletben p értéke 0, 1 vagy 2; Y2 jelentése O,(CH2)q, HC=CH vagy NH; ahol a képletben q értéke 0 vagy 1; Z jelentéseH, OR5 vagy NR6R7; azzal a megkötéssel, hogy amennyiben Z jelentésehidrogénatom, úgy X1 és X2 egyidejűleg nem jelenthet C=O-t, miközbenY1 jelentése (CH2)p, ahol p értéke 0, miközben Y2 jelentése (CH2)q,ahol q értéke 0, és miközben R1 és R2 jelentése egyaránt metilcsoport.A (IV) általános képletben a R1 jelentése adott esetben szubsztituáltaril- vagy adott esetben szubsztituált heteroarilcsoport; R2 jelentéseadott esetben szubsztituált aril- vagy adott esetben szubsztituáltheteroarilcsoport és Y1 jelentése O, (CH2)p, CH2O, HC=CH vagy NH, ahola képletben p értéke 0, 1 vagy 2; és Z jelentése előnyösenhidrogénatom vagy OR5. A (III) általános képletben a szubsztituensek jelentése az (II)általános képlet szerintinél szűkebb körű. Ó
HU0003250A 1996-07-26 1997-07-23 Potassium channel inhibitor indane derivatives and pharmaceutical compositions containing the same HUP0003250A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2254796P 1996-07-26 1996-07-26
US08/893,160 US6083986A (en) 1996-07-26 1997-07-15 Potassium channel inhibitors
PCT/US1997/012559 WO1998004521A1 (en) 1996-07-26 1997-07-23 Potassium channel inhibitors

Publications (2)

Publication Number Publication Date
HUP0003250A1 true HUP0003250A1 (hu) 2002-01-28
HUP0003250A3 HUP0003250A3 (en) 2002-02-28

Family

ID=26696048

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003250A HUP0003250A3 (en) 1996-07-26 1997-07-23 Potassium channel inhibitor indane derivatives and pharmaceutical compositions containing the same

Country Status (13)

Country Link
US (1) US6083986A (hu)
EP (1) EP0923543B1 (hu)
JP (1) JP2002513385A (hu)
KR (1) KR20000029605A (hu)
AT (1) ATE250571T1 (hu)
AU (1) AU734711B2 (hu)
BR (1) BR9710587A (hu)
CA (1) CA2261814A1 (hu)
DE (1) DE69725153T2 (hu)
HK (1) HK1020334A1 (hu)
HU (1) HUP0003250A3 (hu)
IL (1) IL128205A (hu)
WO (1) WO1998004521A1 (hu)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510797A (ja) * 1997-07-22 2001-08-07 イーライ・リリー・アンド・カンパニー 医薬化合物
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
AU754204B2 (en) * 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
CA2383086A1 (en) * 1999-09-08 2001-03-15 Joseph P. Steiner Non-peptidic cyclophilin binding compounds and their use
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
US6458794B2 (en) 1999-12-21 2002-10-01 Icagen, Inc. Potassium channel inhibitors
PT1259484E (pt) 2000-01-18 2005-09-30 Novartis Ag Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b
US6566380B2 (en) 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
AU2002214522A1 (en) * 2000-11-17 2002-05-27 Karolinska Innovations Ab Nucleotide and polypeptide sequences of kcna7, a mammalian voltage-gated potassium channel protein, and use thereof
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US10078087B2 (en) 2001-05-01 2018-09-18 Senomyx, Inc. Assays and enhancers of the human delta ENaC sodium channel
WO2002087306A2 (en) * 2001-05-01 2002-11-07 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
AU2002314132A1 (en) * 2001-05-31 2002-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New heterotetrameric potassium channels and uses thereof
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
AU2004263845A1 (en) 2003-07-10 2005-02-17 Senomyx, Inc. Improved electrophysiological assays using oocytes that express human ENaC and the use of phenamil to improve the effect of ENaC enhancers in assays using membrane potential reporting dyes
DK1742922T3 (en) * 2004-04-01 2016-04-11 Zoetis Services Llc crystalline pyrazole
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US8565898B2 (en) * 2005-04-28 2013-10-22 Medtronic, Inc. Rate control during AF using cellular intervention to modulate AV node
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2010115952A1 (en) * 2009-04-09 2010-10-14 N.V. Organon Indane derivatives
GB0909672D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
NO3175985T3 (hu) 2011-07-01 2018-04-28
TW201319049A (zh) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
HUE038512T2 (hu) 2012-11-13 2018-10-29 Array Biopharma Inc N-pirrolidinil-, N'-pirazolil-karbamid, tiokarbamid, guanidin és cianoguanidin vegyületek mint TrkA kináz inhibitorok
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
HUE031557T2 (hu) 2012-11-13 2017-07-28 Array Biopharma Inc A fájdalom kezelésére használható biciklusos karbamid-, tiokarbamid-, guanidin- és cianoguadinin-vegyületek
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336153A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
PL3154959T3 (pl) 2014-05-15 2019-12-31 Array Biopharma, Inc. 1-((3S,4R)-4-(3-Fluorofenylo)-1-(2-metoksyetylo)pirolidyn-3-ylo)-3-(4-metylo-3- (2- metylopirymidyn-5-ylo)-1-fenylo-1H-pirazol-5-ilo)-mocznik jako inhibitor kinazy TrkA

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB536939A (en) * 1939-08-24 1941-06-03 Eastman Kodak Co Improvements in and relating to photographic colour development
IL62973A0 (en) * 1980-06-02 1981-07-31 Basf Ag Aralkylphenylureas,their manufacture and their use as herbicides
JPS60199862A (ja) * 1984-03-23 1985-10-09 Otsuka Pharmaceut Co Ltd インダン誘導体
GB8707123D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) * 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) * 1987-11-18 1994-05-30 Tanabe Seiyaku Co History of sulfonylamino indane, their preparation and pharmaceutical preparations containing them
DK691488A (da) * 1987-12-14 1989-06-15 Beecham Group Plc Hidtil ukendte forbindelser
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) * 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) * 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) * 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
CA2180841C (en) * 1994-01-10 2007-03-27 Sasson Cohen 1-aminoindan derivatives and compositions thereof
FR2717805B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) * 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU5772396A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0874625B1 (en) * 1996-01-22 2005-03-16 Eli Lilly And Company Indane derivatives for antipsychotic compositions

Also Published As

Publication number Publication date
HUP0003250A3 (en) 2002-02-28
EP0923543A1 (en) 1999-06-23
CA2261814A1 (en) 1998-02-05
HK1020334A1 (en) 2000-04-14
US6083986A (en) 2000-07-04
JP2002513385A (ja) 2002-05-08
BR9710587A (pt) 2000-10-31
WO1998004521A1 (en) 1998-02-05
AU734711B2 (en) 2001-06-21
AU3803597A (en) 1998-02-20
DE69725153T2 (de) 2004-06-09
EP0923543B1 (en) 2003-09-24
IL128205A0 (en) 1999-11-30
IL128205A (en) 2003-09-17
DE69725153D1 (de) 2003-10-30
KR20000029605A (ko) 2000-05-25
ATE250571T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
HUP0003250A1 (hu) Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények
WO1998004521B1 (en) Potassium channel inhibitors
HUP0400694A2 (hu) A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
HUP0103283A2 (hu) Proteázokat gátló pirazinonszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
GB1384031A (en) N-substituted dihydropyridine compounds their production and their medicinal use
UA27901C2 (uk) Похідні 7-(2-аміноетил)бензотіазолону, що проявляють агоністичну активність по відношенню до бета2-адренорецепторів, фармацевтична композиція, спосіб їх отримання та проміжні сполуки
HUP9802290A2 (hu) Pirrolszármazékok és az azokat tartalmazó gyógyászati kompozíciók
HUP0102714A2 (hu) Matrix metalloproteináz inhibitor hatású triciklusos szulfonamidszármazékok és azokat tartalmazó gyógyszerkészítmények
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
HUP0301478A2 (hu) Antibakteriális aktivitású pleuromutilinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE49749T1 (de) Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen.
HUP0104620A2 (hu) 2-Fenil-pirán-4-on-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0104549A2 (hu) Imidazo-piridin szulfonamidszármazékok, és ezeket tartalmazó gyógyszerkészítmények
TR199700354A2 (xx) Karbohidrat t�revleri.
HUP0103166A2 (hu) Karbamát- és karbamidtartalmú készítmények, és neurotróf alkalmazásuk
DK379281A (da) Azolylalkyl-derivater fremgangsmaade til deres fremstilling og deres anvendelse som fungicider
ATE47135T1 (de) Antikonvulsive mittel.
FI870460A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter.
TR199900984T2 (xx) Benzens�lfonamid t�revleri ve ad� ge�en t�revleri i�eren ila�lar.
DK0904270T3 (da) Dihydrobenzofuran og beslægtede forbindelser anvendelige som antiinflammatoriske midler
ES8203837A1 (es) Un procedimiento para la preparacion de derivados de propa- nolamina

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished